Hemogenyx Confirms Updated Share Capital and Voting Rights

An announcement from HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) is now available.

Hemogenyx Pharmaceuticals has confirmed that its total issued share capital as of 30 January 2026 comprises 6,041,255 ordinary shares of 1p each, with none held in treasury, giving the company an equal number of voting rights. This updated share count provides the key denominator for investors to assess and report any holdings or changes in their interests under UK disclosure and transparency rules, ensuring clarity around the company’s capital structure and regulatory compliance for shareholders and market participants.

The most recent analyst rating on (GB:HEMO) stock is a Sell with a £760.00 price target. To see the full list of analyst forecasts on HemoGenyx Pharmaceuticals Plc stock, see the GB:HEMO Stock Forecast page.

Spark’s Take on GB:HEMO Stock

According to Spark, TipRanks’ AI Analyst, GB:HEMO is a Neutral.

The score is held down primarily by very weak financial performance (no revenue, ongoing losses and cash burn, and higher balance-sheet risk from lower equity and increased leverage). Technicals provide some offset with strong recent momentum, but overbought indicators add near-term risk, and valuation support is limited due to a negative P/E and no dividend yield.

To see Spark’s full report on GB:HEMO stock, click here.

More about HemoGenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals plc is a London-headquartered, publicly traded clinical-stage biopharmaceutical group (LSE: HEMO) focused on developing new medicines and treatments for blood and autoimmune diseases. Through its US subsidiaries in New York, Hemogenyx is advancing several complementary product candidates and platform technologies that serve as engines for novel therapeutic development.

Average Trading Volume: 40,204

Technical Sentiment Signal: Buy

Current Market Cap: £49.42M

For a thorough assessment of HEMO stock, go to TipRanks’ Stock Analysis page.